Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

123
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
123
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

229
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
229
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

215
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
215
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

190
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
190
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

162
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
162
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

255
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
255

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bezafibrate for Primary Biliary Cholangitis: a Number Needed to Treat Analysis.

JHEP reports : innovation in hepatology·2026
Same author

Editorial: UDCA Dosing in PBC-Between Guideline Adherence and Clinical Reality: Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective.

The American journal of gastroenterology·2026
Same author

Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.

JHEP reports : innovation in hepatology·2026
Same author

Seronegative Autoimmune Hepatitis in Adults Is a Rare Entity Often Obscured by Suboptimal Diagnostic Assessment.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

From science to public health impact: Enacting the recommendations of the EASL-Lancet Commission on liver health in Europe.

Journal of hepatology·2026

Related Experiment Video

Updated: Aug 27, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical

C Fiorella Murillo Perez1, Holly Fisher2, Shaun Hiu2

  • 1Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.

Gastroenterology
|September 23, 2022
PubMed
Summary

Obeticholic acid (OCA) significantly improved transplant-free survival in Primary Biliary Cholangitis (PBC) patients compared to external controls. This study evaluated liver transplantation or death rates in OCA-treated patients versus non-OCA controls.

Keywords:
Global PBCObeticholic AcidPropensity ScoreTransplant-Free SurvivalUK-PBC

More Related Videos

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

16.6K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.8K

Related Experiment Videos

Last Updated: Aug 27, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

16.6K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.8K

Area of Science:

  • Hepatology
  • Clinical Trials
  • Pharmacology

Background:

  • Primary Biliary Cholangitis (PBC) is a chronic liver disease.
  • Obeticholic acid (OCA) has shown promise in reducing PBC biomarkers.
  • The POISE trial investigated OCA's efficacy in PBC patients.

Purpose of the Study:

  • To evaluate the time to liver transplantation or death in OCA-treated patients.
  • To compare transplant-free survival between OCA-treated patients and external controls.
  • To assess OCA's efficacy in PBC patients with or without cirrhosis.

Main Methods:

  • Randomized, double-blind, placebo-controlled trial (POISE) with open-label extension.
  • Propensity scores generated for external control groups (Global PBC and UK-PBC).
  • Cox proportional hazards models used to assess time to liver transplantation or death.

Main Results:

  • OCA-treated patients had significantly lower rates of liver transplantation or death (2.4%) compared to Global PBC (10.0%) and UK-PBC (13.2%) controls.
  • Hazard ratios for POISE vs. controls were 0.29 and 0.30, indicating reduced risk.
  • Additional analyses showed efficacy including hepatic decompensation and in patients with or without cirrhosis.

Conclusions:

  • OCA treatment in a trial setting significantly enhances transplant-free survival for PBC patients.
  • OCA demonstrates a favorable safety and efficacy profile in managing PBC.
  • These findings support OCA as a valuable therapeutic option for PBC management.